FDA approved Lundbeck’s VYEPTI™ – the first and only intravenous preventive treatment for migraine
On Feb. 21, 2020, Lundbeck announced that VYEPTI™ (eptinezumab-jjmr) had been approved by the U.S. Food and Drug…
Lundbeck acquired Alder BioPharmaceuticals for $1.95 billion
On Oct. 22, 2019, Lundbeck, located in Valby, Denmark, announced it had completed its acquisition of Bothell, Washington-based…
$10 million gift to UCLA from Wendy and Leonard Goldberg largest ever to support migraine research
On Dec. 8, 2015, the University of California, Los Angeles ( UCLA) Health Sciences announced it had received…